ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Smaller Ultrasound-Guided Biopsy Needle Safe, Effective, For Suspected Breast Cancer

May 30, 2003

Home-Based Program Helps Older Cancer Survivors

May 29, 2009

Southwest Oncology Group Becomes “SWOG”

April 8, 2011

Strict Regulation Of Tobacco Products Proposed in Senate

November 24, 1989

Reorganization Of Making Program Is Proposed

June 22, 1990

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

November 28, 2014